KPRX — Kiora Pharmaceuticals, Inc.
$1.23
$-0.13 (-9.56%)
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Market Cap
$5.44M
Forward P/E
-0.6x
52-Week Range
N/A
KPRX Price History
Revenue vs. Net Income
$0
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$10.1M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-58.7%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
3.0x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.0%
CapEx · FY2024
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+1.0%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
